UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of June, 2020

Commission File Number: 001-37891

AC IMMUNE SA

(Exact name of registrant as specified in its charter)

EPFL Innovation Park
Building B
1015 Lausanne, Switzerland
(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F X Form 40-F _____

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Yes _____ No X

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

Yes _____ No X

Annual Ordinary Shareholders' Meeting Results

On June 26, 2020, AC Immune SA ("**AC Immune**") held its annual Ordinary Shareholders' Meeting. The presentation that was given at the Ordinary Shareholders' Meeting is attached hereto as Exhibit 99.1 and the press release relating to the results of the Ordinary Shareholders' Meeting is attached hereto as Exhibit 99.2. The final results of each of the agenda items submitted to a vote of the shareholders are as follows:

Agenda Item 1: Approval of the Annual Report, Annual Statutory Financial Statements and Financial Statements under IFRS of AC Immune SA for the year 2019

AC Immune shareholders approved the Annual Report, the Annual Statutory Financial Statements and the Financial Statements under IFRS of AC Immune SA for the year 2019, and took note of the Reports of the Auditors.

Agenda Item 2: Appropriation of Profit

AC Immune shareholders approved that the profit for the year 2019 in the amount of KCHF 45,169 reduces the "accumulated losses brought forward" of KCHF 107,320, resulting in a new balance of "accumulated losses brought forward" of KCHF 62,151.

Agenda Item 3: Discharge of the Members of the Board of Directors and the Executive Committee

AC Immune shareholders approved the discharge of the Board and the Executive Committee of their liabilities for their activities in the financial year 2019.

Agenda Item 4: Compensation for the Members of the Board of Directors and the Executive Committee

AC Immune shareholders approved:

A. The total maximum amount of non-performance-related compensation for the members of the Board of Directors covering the period from 1 July 2020 to 30 June 2021, *i.e.*, CHF 565,000 (cash based compensation plus pensionable social security costs);

B. The maximum grant of equity or equity linked instruments for the members of the Board of Directors from 1 July 2020 to 30 June 2021 with maximum value of CHF 635,000 (equity or equity linked instruments at grant value plus pensionable social security costs);

C. The total maximum amount of non-performance-related cash compensation for the members of the Executive Committee from 1 July 2020 to 30 June 2021, *i.e.*, CHF 2,778,000 (cash based compensation plus pensionable social security costs);

D. The total maximum amount of variable compensation for the members of the Executive Committee for the current year 2020, *i.e.*, CHF 1,133,000 (cash based compensation plus pensionable social security costs);

E. The maximum grant of equity or equity linked instruments for the members of the Executive Committee from 1 July 2020 to 30 June 2021 with maximum value of CHF 3,496,000 (equity or equity linked instruments at grant value plus pensionable social security costs); and

F. The 2019 Remuneration Report as filed with the US Securities and Exchange Commission as Annex 99.3 to the Company's March 30, 2020 Form 6-K filing.

Agenda Item 5: Re-elections

Agenda Item 5.1: Re-elections of the Members of the Board

AC Immune shareholders approved the re-election of Douglas Williams as member and as Chairman of the Board, the re-election of Martin Velasco as member and as Vice-Chairman of the Board, the re-election of Peter Bollmann, Andrea Pfeifer, Tom Graney, Werner Lanthaler and Roy Twyman as members of the Board of Directors, each until the end of the next Ordinary General Meeting.

Agenda Item 5.2: Re-elections to the Compensation, Nomination & Corporate Governance Committee

AC Immune shareholders approved the re-election of Martin Velasco, Tom Graney and Douglas Williams as members of the Compensation, Nomination & Corporate Governance Committee, each until the end of the next Ordinary General Meeting.

Agenda Item 5.3: Re-elections of the Statutory Auditors

AC Immune shareholders approved the re-election of PricewaterhouseCoopers SA, in Pully, for a term of office of one year.

Agenda Item 5.4: Re-election of the Independent Proxy

AC Immune shareholders approved the re-election of Reymond & Associés, represented by Denis Cherpillod as AC Immune's independent proxy until the end of the next Ordinary General Meeting.

Agenda Item 6: Amendments to the Articles of Association

Agenda Item 6.1: Authorized Share Capital

AC Immune shareholders approved an amendment to the existing first paragraph of article 3a (Authorized Capital Increase of Share Capital) of the articles of association pertaining to a proposed increase by the Board of Directors in AC Immune's share capital, in one or several steps, until 27 June 2022, by a maximum amount of CHF 290,000 by issuing a maximum of 14,500,000 registered shares with a par value of CHF 0.02 each, to be fully paid up. An increase of the share capital (i) by means of an offering underwritten by a financial institution, a syndicate or another third party or third parties, followed by an offer to the then-existing shareholders of the Company and (ii) in partial amounts, shall also be permissible.

Agenda Item 6.2: Conditional Capital Increase for Bonds and Similar Debt Instruments

AC Immune shareholders approved an amendment to the existing first paragraph of article 3b (Conditional Capital Increase for Bonds and Similar Debt Instruments) of the articles of association pertaining to the increase of the share capital of the company by a maximum amount of CHF 91,560.94 through the issue of a maximum of 4,578,047 registered shares, payable in full, each with a nominal value of CHF 0.02, through the exercise of conversion and/or option or warrant rights granted in connection with bonds or similar instruments, issued or to be issued by the Company or by subsidiaries of the Company, including convertible debt instruments.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

AC IMMUNE SA

By: /s/ Andrea Pfeifer
Name: Andrea Pfeifer
Title: Chief Executive Officer

By: /s/ Joerg Hornstein
Name: Joerg Hornstein
Title: Chief Financial Officer

Date: June 26, 2020

EXHIBIT INDEX

Exhibit Number	Description
99.1	Annual Ordinary Shareholders' Meeting presentation
99.2	Press Release dated June 26, 2020

Pioneering Precision Medicine for Neurodegeneration

NASDAQ: ACIU | Annual General Meeting | June 26, 2020

AC Immune

www.acimmune.com

Disclaimer

This presentation contains statements that constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements are statements other than historical fact and may include statements that address future operating, financial or business performance or AC Immune's strategies or expectations. In some cases, you can identify these statements by forward-looking words such as "may," "might," "will," "should," "expects," "plans," "anticipates," "believes," "estimates," "predicts," "projects," "potential," "outlook" or "continue," and other comparable terminology. Forward-looking statements are based on management's current expectations and beliefs and involve significant risks and uncertainties that could cause actual results, developments and business decisions to differ materially from those contemplated by these statements. These risks and uncertainties include those described under the captions "Item 3. Key Information – Risk Factors" and "Item 5. Operating and Financial Review and Prospects" in AC Immune's Annual Report on Form 20-F and other filings with the Securities and Exchange Commission. These include: the impact of Covid-19 on our business, suppliers, patients and employees and any other impact of Covid-19. Forward-looking statements speak only as of the date they are made, and AC Immune does not undertake any obligation to update them in light of new information, future developments or otherwise, except as may be required under applicable law. All forward-looking statements are qualified in their entirety by this cautionary statement.

This presentation is strictly confidential, is being distributed to a limited range of invited persons solely for their own information, may not be distributed to the press or any other person, and may not be reproduced or published, in whole or in part, in any form.

Agenda

1. AC Immune's leadership in neurodegenerative diseases
2. Achievements 2019/20
3. AC Immune's business strategy
4. Pipeline update
5. Novel drug targets for neurodegenerative diseases
6. Near-term inflection points
7. Financial figures
8. Strategic outlook



1. AC Immune's leadership in neurodegenerative diseases

Andrea Pfeifer, CEO

Roadmap to successful therapies for NDDs[1]

AC Immune

Precision medicine is a key driver for effective treatments



(1) Neurodegenerative diseases; (2) Reardon S. Nature 2018; (3) Pontecorvo MJ, *et al.*, Brain 2019; (4) Gordon BA, *et al.*, Brain 2019 ; (5) Positron emission tomography; (6) Strydom A, *et al.*, Alzheimers Dement (NY) 2018; (7) Lott IT and Head E.,Nat Rev Neurol. 2019; (8) Robinson JL, *et al.*, Brain 2018; (9) Heneka MT *et al.*, Nat Rev Neurosci. 2018; (10) Wang S *et al.*, Int Immunopharmacol. 2019 ; (11) (NOD)-like receptor protein 3; (12) Apoptosis-associated speck protein containing a CARD

AC Immune is focused on precision medicine in AD[1] and NDD[2]

Multiple targets and approaches enable mono- and combination therapies



(1) Alzheimer's disease; (2) Neurodegenerative diseases; (3) Mild cognitive impairment

- Future treatment paradigms for NDD may involve different combinations of disease modifiers at various stages of a disease
- Combination therapies may include combinations of immunotherapies or combinations of small and large molecules targeting proteinopathies and neuroinflammation



2. Achievements 2019/20

Covid-19: minimal anticipated impact on milestone achievement

Not modifying guidance: remain on track to deliver five clinical readouts in 2020

Executing robust business continuity plan	▪ Making every provision to protect the health of patients, staff, and investigators ▪ In continuous coordination with partners and important stakeholders including the Swiss government, trial investigators and contractors ▪ Maintaining productivity and integrity of our clinical development
On track to deliver 2020 milestones	▪ Many key trials are already fully enrolled ▪ Patient follow up continuing virtually
Additional considerations	▪ ACI-24 in AD[1]: Phase 2, 12-month interim data analysis will proceed as planned on a reduced patient data-set ▪ ACI-24 in DS[2]: Plans to initiate Phase 2 in H2 2020 are progressing; to be initiated in line with public health guidance at that time ▪ Crenezumab: Phase 2 (API) study: Dosing temporarily interrupted due to country-wide order; patients dosed for >5 years as part of prevention study and data still anticipated in 2022

(1) Alzheimer's disease; (2) Down syndrome

2019: Strong pipeline progress and further improved balance sheet

Building on our track record of successful execution

Achieving partnership milestones	✓ CHF 110 million from Lilly for small molecule Tau inhibitor and $50 million in exchange for a note, convertible to equity at a premium ✓ Milestone payment for Tau PET tracer entering Phase 2 ✓ New grant from MJFF for a-synuclein PET tracer
Advancing/expanding clinical pipeline	✓ Second Phase 2 trial of semorinemab in moderate AD ✓ Phase 1b/2a trial of anti-phospho-Tau vaccine ✓ Phase 1 trial of small molecule Tau inhibitor ✓ Tau imaging substudy in ongoing API study of crenezumab
Delivering program readouts	✓ a-synuclein and TDP-43 Proof of Concept (PoC) studies in Q3 2019 ✓ Interim Phase 1b data for anti-Abeta vaccine in Down syndrome ✓ Interim Phase 1b of anti-pTau vaccine ACI-35 ✓ Phase 1 SAD results for small molecule Tau inhibitor
Establishing thought leadership	✓ Key opinion leader (KOL) event on “untangling Tau pathology” ✓ KOL event on treated AD in people with Down syndrome
Unlocking platform potential	✓ Novel biparatopic antibodies against a-synuclein



3. AC Immune’s business strategy

AC Immune strengths

A leader in neurodegenerative diseases

1. Addressing the largest market opportunity in healthcare
   - Pioneering precision medicine in neurodegenerative diseases
2. Highly productive validated discovery platforms for sustained growth to address misfolded proteins applicable across multiple diseases
   - SupraAntigen™: vaccines and antibodies specific to disease-causing conformations
   - Morphomer™: conformation-sensitive small molecules
3. Broad pipeline with four therapeutic candidates in Phase 2
   - Multiple near-term value inflection points
   - Partnerships with Roche, Janssen Pharmaceuticals and Eli Lilly and Company
4. Complementary diagnostics in clinical development
   - Highly-valued preclinical assets in Tau, a-syn and TDP-43
5. CHF 277.9 million in cash[1]; sufficiently funded to reach multiple value inflection points through at least Q1 2024
   - Increasing investment into key areas of NeuroOrphan and neuroinflammation

(1) As of March 31, 2020

Vision

*To become a global leader in **precision medicine**[1] for neurodegenerative diseases leveraging dual proprietary technology platforms to develop breakthrough mono- and combination therapies*

Clinically Validated Technology Platforms

SupraAntigen™

Vaccines and antibodies specific to disease causing conformations





Morphomer™

Conformation-sensitive small molecules

Images: Hickman *et al.*, JBC 2011; Kroth *et al.*, JBC 2012

(1) The goal of precision medicine is to deliver optimally targeted and timed interventions tailored to the individual disease drivers

Unlocking platform potential for next generation of innovations

Multiple opportunities for value creation and future partnership

Monoclonal antibodies	Bispecific antibodies	Biparatopic antibodies	Conformational liposomal vaccines	Small molecule therapeutics	PET[1] tracers diagnostics
					
SupraAntigen™				**Morphomer™**	
▪ semorinemab *(anti-Tau)* Genentech ▪ crenezumab *(anti-Abeta)* Genentech ▪ anti-a-syn ▪ anti-TDP-43 ▪ anti-ASC[3] (NI[4])	▪ undisclosed	▪ a-syn ▪ undisclosed	▪ ACI-35 *(anti-pTau vaccine)* janssen ▪ ACI-24 *(anti-Abeta vaccine)*	▪ ACI-3024 *(Tau inhibitor)* Lilly ▪ a-syn inhibitor ▪ NLRP3[2] inhibitor	▪ PI-2620 *(Tau tracer)* Life Molecular Imaging ▪ a-syn tracer ▪ TDP-43 tracer

(1) Positron emission tomography; (2) (NOD)-like receptor protein 3; (3) Apoptosis-associated speck protein containing a CARD; (4) Neuroinflammation

Business strategy: three-pillar approach

Precision medicine ultimately creates differentiation



Alzheimer's disease (AD)

- Develop best-in-class late stage assets in partnership
- Develop preventive/therapeutic vaccines as fully owned assets (ACI-24)
- Establish a pipeline of disease-modifying small molecules

Non-AD, NeuroOrphans

- Discover therapeutics in Parkinson's disease
- Leverage AD therapeutics in Down syndrome, PSP[1] and other NeuroOrphan diseases
- Target neuroinflammation for NDD[2] as mono- and/or combination therapy

Diagnostics

- Accelerate diagnostic pipeline to late stage development
- Use diagnostics for improved clinical trials and external partnerships

(1) Progressive supranuclear palsy; (2) Neurodegenerative diseases



4. Pipeline update

Broad and robust pipeline in neurodegenerative diseases

Driven by validated proprietary technology platforms for sustained growth

Clinical-stage pipeline (★ data readout expected in 2020)

TARGET	PRODUCT CANDIDATE	INDICATION	DISCOVERY	PRECLINICAL	PHASE 1	PHASE 2	PHASE 3	PARTNER
Tau	**semorinemab** *(anti-Tau antibody)*	AD[1] treatment *(prodromal / mild)*					★	Genentech
		AD treatment *(moderate)*						
	ACI-35.030 *(anti-pTau vaccine)*	AD treatment				★		janssen
	ACI-3024 *(Tau inhibitor)*	AD treatment			★			Lilly
	Tau-PET[2] tracer	AD and PSP[3]						Life Molecular Imaging
Abeta	**crenezumab** *(anti-Abeta antibody)*	AD prevention[4]						Genentech
	ACI-24 *(anti-Abeta vaccine)*	AD treatment (*Down syndrome[5]*)				★		
		AD treatment					★	

Biologic
Small Molecule
Diagnostic

(1) Alzheimer's disease; (2) Positron emission tomography; (3) Progressive supranuclear palsy; (4) Prevention trial API-ADAD in Colombia; (5) AD-like cognitive impairment associated with Down syndrome

Broad and robust pipeline in neurodegenerative diseases

Driven by validated proprietary technology platforms for sustained growth

Early-stage pipeline (★ key milestone in 2020)

TARGET	PRODUCT CANDIDATE	INDICATION	DISCOVERY	PRECLINICAL	PHASE 1
a-synuclein (a-syn)	a-syn-PET[1] tracer	PD[2], a-synucleinopathies			★
	anti-a-syn antibody	PD, NeuroOrphan		★	
	Morphomer a-syn *(a-syn inhibitor)*	PD, a-synucleinopathies		★	
TDP-43[3]	anti-TDP-43 antibody	NeuroOrphan		★	
	TDP-43-PET tracer	TDP-43-opathies			
Inflammasome	anti-NLRP3[4]-ASC[5] antibody	NeuroOrphan		★	
	Morphomer-NLRP3-ASC	Non-CNS[6]		★	
	Morphomer-NLRP3-ASC	NeuroOrphan			

Biologic
Small Molecule
Diagnostic

(1) Positron emission tomography; (2) Parkinson's disease (3) TAR DNA-binding protein 43; (4) (NOD)-like receptor protein 3; (5) Apoptosis-associated speck protein containing a CARD; (6) Central nervous system



5. Novel drug targets for neurodegenerative diseases

Why do we need precision medicine in AD[1]?

High level of other proteinopathies and co-pathologies in AD

hAD[2] (iAD[3]) shows high levels of co-pathologies:

- 55% (41%) a-syn;
- 40% (33%) TDP-43 with an overall prevalence of 70% (65%) of co-pathologies



Adapted from Robinson et al. Brain, 2018

iAD[3]; intermediate; hAD[2], high levels of co-pathologies

- The prevalence of co-pathologies in AD[1] and other NDD[4] may indicate a need for different therapies at different stages
- Clinical trial participants may be better defined by their various proteinopathies
- Patient sub-classification may lead to improved clinical outcome
- Combination therapy may be the ultimate requirement

(1) Alzheimer's disease; (2) High level of Alzheimer's disease neuropathological change; (3) Intermediate level of Alzheimer's disease neuropathological change; (4) Neurodegenerative diseases

TDP-43[1] and alpha-synuclein: drivers of value creation in 2020 and beyond

Broad applications in NDD and AD

Established hallmarks in NDD	Including NeuroOrphan indications and Parkinson's disease
Novel therapeutic targets in Alzheimer's disease	High levels of a-syn and/or TDP-43 co-pathology
Highlights the need for precision medicine	For faster and more accurate diagnosis, treatment and monitoring of disease progression
Significant market opportunity	AC Immune's therapeutic and diagnostic programs are amongst the most comprehensive in the field

(1) TAR DNA-binding protein 43

Emerging targets in neurodegenerative disease

Antibodies targeting TDP-43[1] and a-syn[2]

Misfolded proteins form aggregates and inclusion bodies leading to neuronal death



1 Bind extracellular aggregates

Aggregates spread extracellularly in a "prion-like" fashion

2 Enhance phagocytic clearance

3 Inhibit seeding and spreading

(1) TAR DNA-binding protein 43; (2) Alpha-synuclein; (3) Neurodegenerative diseases; (4) Alzheimer's disease

Only anti-TDP-43 antibody reported with demonstrated *in vivo* activity

Established preclinical proof-of-concept

Inhibition of TDP-43 aggregation *in vitro*

Recombinant TDP-43 aggregation assay



Reduction of pathological TDP-43 *in vivo*[1]

pTDP-43[2] (Immunohistochemistry)



Insoluble TDP-43 (biochemistry)



Key results	▪ *In vitro*, 98% inhibition of TDP-43 aggregation ▪ *In vivo*, significant reduction in TDP-43 neuro-pathology
Next steps	▪ Complete humanization of lead candidate; start IND[3]-enabling studies in **Q2 2020**

(1) rNLS8 TDP-43 transgenic mouse model; Walker *et al.*, Acta Neuropathol., 2015; (2) Phosphorylated TDP-43; (3) Investigational new drug

First-in-class TDP-43 PET[1] imaging tracer – Discovery Phase

Designed to facilitate clinical development and enable precision medicine

Binding affinity on FTD type-C brain-derived TDP-43 aggregates



Target engagement by micro-autoradiography



Brain PK[2] profile



Ref: AC Immune unpublished data

Key results	▪ Lead candidate shows selective TDP-43 binding ▪ Target engagement confirmed by micro-autoradiography ▪ PK study confirmed good, rapid brain uptake (4.11%)
Next steps	▪ Further optimize target affinity and PK profile; declare clinical lead candidate

(1) Positron emission tomography; (2) Pharmacokinetic

Lead candidate ACI-5755 currently in IND[1]-enabling studies in PD[2]

Targeting spreading of pathological a-syn with selective antibody

Inhibition of a-syn aggregation *in vitro*

Recombinant a-syn aggregation assay



Cellular spreading assay[4]



Reduction of pathological a-syn *in vivo*[3]

Phosphorylated S129 a-syn (p-Syn[5]) cortex immunohistochemistry



Ref. AC Immune data presented at AD/PD 2020

Key results	▪ *In vitro*, ACI-5755 significantly inhibits a-syn aggregation and inhibits uptake and seeding capacity of a-syn aggregates in cells ▪ *In vivo*, ACI-5755 significantly decreases a-syn spreading
Next steps	▪ Advance towards IND filing

(1) Investigational new drug; (2) Parkinson's disease; (3) M83 transgenic mice inoculated with human a-syn preformed fibrils; (4) Human cell line susceptible to a-syn seeding; (5) p-syn antibody (pSer129; Abcam, UK)

A-syn PET[1] imaging tracer – First-in-Human

Potentially the first selective diagnostic agent for PD[2]

THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH

Biochemical and histological radiography assays

Binding to Lewy bodies in PD brains



Binding to PD-derived a-syn aggregates



Pharmacokinetic (PK) profile in NHP[3]

18F-PK profile in different brain regions[4]



Brain uptake		Wash-out
Time to C_{max}	ID/g[6] brain (%)	Peak/half Peak
5min	4.0	~ 20min

Capotosti, AD/PD Conference, Lisbon 2019

Key results	▪ Highly specific, low nanomolar binding in human PD, DLB[7] and MSA[8] brains ▪ Between 500 to 1000-fold selectivity over potential Abeta co-pathologies ▪ Favorable PK profile in NHPs and mice
Next steps	▪ 2nd-gen study in genetic populations, i.e. MSA and SNCA[9] ▪ Advance 3rd-gen candidate to clinical stage in **Q4 2020**

(1) Positron emission tomography; (2) Parkinson's disease; (3) Non-human primates; (4) Data shown for 18F-labeled ACI-3710 by positron emission tomography (PET); (5) Square of the coefficient of multiple correlation; (3) Non-human primates; (4) Data shown for 18F-labeled ACI-3710 by PET[1]; (6) Injected dose per gram of brain; (7) Dementia with Lewy bodies; (8) Multiple system atrophy; (9) Alpha-synuclein gene mutation

AC Immune



6. Near-term inflection points

Multiple upcoming clinical catalysts to drive value in 2020

1st
Tau antibody
Phase 2 data expected

3
Tau programs reporting clinical data

5
clinical readouts expected this year

Phase 2 readouts

- semorinemab — mild / prodromal AD
- ACI-24 — AD (interim data)

Phase 1b readouts

- ACI-35.030[1] — AD (interim data)
- ACI-24 — Down syndrome

Phase 1 readouts

- ACI-3024 — healthy volunteers

Initiation

- ACI-24 — Phase 2 – Down syndrome

(1) Phase 1b/2a study

Multiple upcoming catalysts to drive value in 2020



(1) Alzheimer's disease; (2) Cohort 1; safety/tolerability; immunogenicity; (3) Phase 1b completion expected in Q2; (4) AD-like cognitive impairment associated with Down syndrome; (5) Phase 1 completion expected in Q2; (6) Investigational new drug; (7) Parkinson's disease; (8) TAR DNA-binding protein 43; (9) (NOD)-like receptor protein 3; (10) Apoptosis-associated speck protein containing a CARD; (11) Central nervous system



7. Financial figures

Substantial funds from partnerships complement equity investments

Distinguished institutional investors[1]

B.A:M:

BlackRock

BVF PARTNERS L.P.

Fidelity

INVUS

Prosight Capital

TEKLA Capital Management LLC

TEMASEK

Corporate funding to date[2] (in CHF millions)

CHF 313 million



CHF 334 million

- CHF 313 million from investor funds
- CHF 334 million in partnering related funds[3,4]
- CHF 3 billion in total potential payments plus potential royalties outstanding

(1) Based on latest schedule 13G and 13F filings; (2) Converted to CHF based on exchange rates at times of receipt; (3) Milestone payments as of March 31, 2020; (4) With Lilly convertible loan

2019 Financial update

Strong cash position	▪ CHF 288.6 million compared to CHF 186.5 million at December 31, 2018
Substantial partnership revenues	▪ Received CHF 111.0 million in 2019, an increase of CHF 103.8 million compared to 2018
R&D expenses	▪ Increased by CHF 6.2 million year-over-year to CHF 50.4 million in 2019
G&A expenses	▪ Increased by CHF 3.6 million year-over-year to CHF 16.1 million in 2019
IFRS income/(loss)	▪ Net income after taxes of CHF 45.4 million in 2019, compared with net loss of CHF 50.9 million in 2018

Sufficiently funded to reach multiple value inflection points through at least Q1 2024[1]

(1) Excluding potential future milestone payments



8. Strategic outlook

Drivers of value creation in 2020 and beyond

Ongoing strong financial position	CHF 277.9 million in cash[1], ensuring the Company is fully financed through Q1 2024
Pipeline progression	Industry-leading molecules against multiple key targets; i.e. anti-a-syn and anti-TDP-43 antibodies advancing to preclinical development
5 clinical data readouts in 2020	Multiple near-term value inflection points, including the 1st Phase 2 readout of an anti-Tau antibody in Alzheimer's disease
Pioneering precision medicine	Addressing large market opportunity with differentiated, patient-focused approach

(1) As of March 31, 2020

We continue to shape the future of neurodegeneration by discovering and developing breakthrough therapies through pioneering science and precision medicine

AC Immune

PRESS RELEASE

AC Immune Announces Results of Annual General Meeting

Lausanne, Switzerland, 26 June, 2020 – AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, announced AC Immune shareholders approved all of the resolutions as proposed by the Board of Directors at today's Annual General Meeting (AGM) in Lausanne.

At the AGM, shareholders re-elected Douglas Williams, Martin Velasco, Peter Bollmann, Andrea Pfeifer, Thomas Graney, Werner Lanthaler and Roy Twyman to their positions on the Board of Directors. Douglas Williams and Martin Velasco will continue to serve as Chairman and Vice-Chairman of the Board, respectively.

Douglas Williams, Chairman of the Board, said: "The Company is gathering momentum on the back of strong progress, and we remain on track to meet multiple value-creating milestones this year with five clinical readouts expected in 2020. We are especially excited about the Phase 2 trial evaluating our anti-Tau antibody semorinemab in Alzheimer's disease. The primary completion of the trial is expected soon and we expect top line data in the second half of 2020. We are also extremely pleased to report AC Immune's solid financial position, with operations fully funded through at least Q1 2024."

AC Immune has always maintained a robust business continuity plan. During the Covid-19 outbreak, every provision has been made to protect the health of patients, staff and investigators, as well as the productivity and integrity of our clinical development. Importantly, we currently remain on track to deliver all clinical and preclinical readouts expected in 2020. The Swiss Government's management of Covid-19 means that businesses have been able to return to near normal working practices with all AC Immune staff now back on site in Lausanne.

As part of its efforts to ensure stakeholder safety during the Covid-19 outbreak, AC Immune held only the mandatory part of the AGM as stipulated by Swiss law and by the Company's Articles of Association. Voting took place via the independent proxy.

About AC Immune SA

AC Immune SA is a Nasdaq-listed clinical-stage biopharmaceutical company, which aims to become a global leader in precision medicine for neurodegenerative diseases. The Company utilizes two proprietary platforms, SupraAntigen™ and Morphomer™, to design, discover and develop small molecule and biological therapeutics as well as diagnostic products intended to diagnose, prevent and modify neurodegenerative diseases caused by misfolding proteins. The Company's pipeline features nine therapeutic and three diagnostic product candidates, with six currently in clinical trials. It has collaborations with major pharmaceutical companies including Roche/Genentech, Eli Lilly and Company and Janssen Pharmaceuticals.

For further information, please contact:

Head of Investor Relations
Joshua Drumm, Ph.D.
AC Immune
Phone: +1 917 809 0814
Email: joshua.drumm@acimmune.com

US Media
Katie Gallagher
LaVoieHealthScience
Phone: +1 617 792 3937
Email: kgallagher@lavoiehealthscience.com

Global Head of Communications
Judith Moore
AC Immune
Phone: +41 79 826 63 82
Email: judith.moore@acimmune.com

European Investors & Media
Chris Maggos
LifeSci Advisors
Phone: +41 79 367 6254
Email: chris@lifesciadvisors.com

Forward looking statements

This press release contains statements that constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements are statements other than historical fact and may include statements that address future operating, financial or business performance or AC Immune’s strategies or expectations. In some cases, you can identify these statements by forward-looking words such as “may,” “might,” “will,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “projects,” “potential,” “outlook” or “continue,” and other comparable terminology. Forward-looking statements are based on management’s current expectations and beliefs and involve significant risks and uncertainties that could cause actual results, developments and business decisions to differ materially from those contemplated by these statements. These risks and uncertainties include those described under the captions “Item 3. Key Information – Risk Factors” and “Item 5. Operating and Financial Review and Prospects” in AC Immune’s Annual Report on Form 20-F and other filings with the Securities and Exchange Commission. These include: the impact of Covid-19 on our business, suppliers, patients and employees and any other impact of Covid-19. Forward-looking statements speak only as of the date they are made, and AC Immune does not undertake any obligation to update them in light of new information, future developments or otherwise, except as may be required under applicable law. All forward-looking statements are qualified in their entirety by this cautionary statement.